ArticleCurrent therapeutic research, clinical and experimental2025
Anti-Gastric Cancer Activity of Mixed-Region Iranian Propolis Nanoparticles: Potential Therapeutic Applications.
Article in Current therapeutic research, clinical and experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Assessment of the Effect of Nano Propolis Against Melanoma Cell Line, and Its Radio Sensitization Effect.Food science & nutrition · 2026Article
- Enhancing Cancer Therapy with Hyperthermia: Synergistic Effects with Natural Compounds and Conventional Treatments.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Propolis holds great potential in therapeutic development due to the presence of flavonoids, phenolic acids, and esters. However, its chemical composition has restricted its solubility and bioaccessibility. Here, we synthesized responsive Iranian propolis nanoparticles derived from 3 distinct regions of Iran, representing the first comparative investigation of their anticancer effects against AGS gastric cancer cells. Methods: Propolis was collected from 3 different regions of Iran. Iranian propolis extract (IPE) was prepared using Bosio method. Quantitative and qualitative analyses were performed. Using the probe sonication, Iranian propolis nanoparticles (IPNs) were prepared. Identification tests of IPNs were performed with dynamic light scattering (DLS)-Zetasizer methods. Next, the anticancer potential of IPNs was analyzed by measuring the cell survival rate on the AGS gastric cancer cell line by MTT assay. Also, the IPNs apoptotic activity was evaluated using Annexin V/FITC-propidium iodide (PI) flow cytometry. Results: Analysis of the IPE showed the presence of paracoumaric acid and caffeic acid predominantly. An average IPNs size was obtained from 8 to 15 nm with good stability and cellular uptake. Compared with IPE, IPNs showed a greater effect on AGS gastric cancer cell survival inhibition after 24 and 48 h. The IC50 values of cancer cells treated with IPE and IPNs were calculated as 76.55 and 43.26 µg/ml for 24 h and 63.26 and 12.14 µg/ml for 48 h respectively. The flow cytometry results showed that the apoptosis induced by IPNs was greater than the control cells. Conclusions: Our study indicated that the IPNs can be more effective than IPE in reducing AGS cell viability and increasing apoptosis. These results suggest the potential of IPNs as low-toxicity nanocarriers for gastric cancer therapy, although further in vivo studies are required to validate their therapeutic potential and assess their pharmacokinetic properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.